Page last updated: 2024-11-04

itopride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3792
CHEMBL ID2107457
CHEBI ID94809
SCHEMBL ID311309
MeSH IDM0267793

Synonyms (53)

Synonym
AB00698504-09
itax
hsr 803
itopride
NCGC00167529-01
HMS2090M18
L002674
itopride (inn)
D08094
122898-67-3
n-{4-[2-(dimethylamino)ethoxy]benzyl}-3,4-dimethoxybenzamide
HMS3264A06
unii-81bmq80qrl
n-(p-(2-(dimethylamino)ethoxy)benzyl)veratramide
nsc 759643
81bmq80qrl ,
itopride [inn]
nsc-759643
nsc759643
pharmakon1600-01502353
CHEMBL2107457
FT-0631111
itopride [who-dd]
itopride [mi]
STL483803
DB04924
CCG-213830
SCHEMBL311309
AB00698504-07
AKOS022172837
n-[4-[2-(dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide
DTXSID7048320
n-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzamide
AB00698504_10
Z667612124
SR-01000763470-4
SR-01000763470-3
sr-01000763470
CHEBI:94809
n-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide
HMS3713O06
Q4409774
itopride free base
122898-67-3 (free base)
BCP12218
benzamide, n-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxy-
n-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4-dimethoxybenzamide
STR09779
(z)-4-morpholin-4-yl-4-oxobut-2-enoicacid
A890881
CS-0013633
HY-B0732A
EN300-6492966

Research Excerpts

Overview

Itopride is an effective and well-tolerated drug in the treatment of functional dyspepsia in the Russian patients. Itopride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions.

ExcerptReferenceRelevance
"Itopride, is a prokinetic agent which is different and unique from the available prokinetics because of its dual mode of action as well as its tolerability and safety."( The efficacy and safety of itopride in feeding intolerance of critically ill patients receiving enteral nutrition: a randomized, double-blind study.
Bassiouny, AM; Darweesh, EAG; El Borolossy, RM; Elmokadem, EM; Hanna, MG; Sabri, NA, 2021
)
1.64
"Itopride is an effective gastroprokinetic agent mainly used for the treatment of functional dyspepsia. "( Effect of two-linked mutations of the FMO3 gene on itopride metabolism in Chinese healthy volunteers.
Chen, H; Chen, Y; Guo, D; Huang, WH; Tan, ZR; Wang, LS; Zhang, GG; Zhou, LP, 2014
)
2.1
"Itopride is an effective and well-tolerated drug in the treatment of functional dyspepsia in the Russian patients."( [Use of itopride in the symptoms of functional dyspepsia in Russia: results of a phase IV prospective open-label multicenter clinical trial].
Denisov, NL; Kas'ianenko, VI; Vasil'ev, IuV, 2014
)
2.28
"Itopride is a new prokinetic agent that combines antidopaminergic and cholinesterase inhibitory actions. "( The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man.
Blondeau, K; Boecxstaens, V; Farré, R; Gasbarrini, A; Scarpellini, E; Tack, J; Vos, R, 2011
)
2.16
"Itopride is a novel prokinetic agent with a dual mode of action, good safety profile and documented efficacy in placebo-controlled trials."( Itopride in the treatment of functional dyspepsia in Chinese patients: a prospective, multicentre, post-marketing observational study.
Holtmann, G; Sun, J; Yuan, YZ, 2011
)
2.53
"Itopride is a prokinetic agent that has anticholinesterase activity as well as dopamine D(2) receptor antagonistic activity."( Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers.
Bae, KS; Choi, HY; Jang, SB; Jin, SJ; Kim, MJ; Kim, YH; Lee, SJ; Lim, HS; Noh, YH; Sung, H, 2012
)
1.33
"Itopride is a newly developed prokinetic agent, which enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions. "( Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study.
Choi, CS; Choi, MG; Choi, SC; Kim, SW; Kim, TH; Kim, YS; Nah, YH; Seo, GS; Shon, YW, 2005
)
2.17
"Itopride is a new safer prokinetic drug with dopamine D2 antagonism and acetylcholinesterase inhibitory actions."( Evaluation of new gastro-intestinal prokinetic (ENGIP-II) study.
Bargaje, RS; Kulkarni, SS; Walwaikar, PP, 2005
)
1.05

Effects

Itopride has good efficacy in terms of global patients assessment, postprandial fullness, and early satiety in the treatment of patients with FD. Itopride shows a low rate of adverse reactions.

ExcerptReferenceRelevance
"Itopride has prokinetic effects on both the ileum and colon, which are regulated through inhibitory effects on AChE and antagonistic effects on dopamine D(2) receptor."( Effect of itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro.
Kim, HS; Kim, YG; Lim, HC; Lim, JH; Park, H, 2008
)
2.19
"Itopride has good efficacy in terms of global patients assessment, postprandial fullness, and early satiety in the treatment of patients with FD and shows a low rate of adverse reactions. "( Itopride therapy for functional dyspepsia: a meta-analysis.
Fan, YH; Huang, X; Lv, B; Meng, LN; Zhang, S, 2012
)
3.26

Treatment

Itopride pre-treatment inhibited the meal-induced rise of transient LES relaxations (TLESRs) With itopride treatment, the emptying of both solids and liquids tended to be more accelerated.

ExcerptReferenceRelevance
"Itopride pre-treatment inhibited the meal-induced rise of transient LES relaxations (TLESRs)."( The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man.
Blondeau, K; Boecxstaens, V; Farré, R; Gasbarrini, A; Scarpellini, E; Tack, J; Vos, R, 2011
)
1.44
"With itopride treatment, the emptying of both solids and liquids tended to be more accelerated, as the emptying with placebo was slower (solids: r = 0.39, P = 0.057; liquids: r = 0.44, P < 0.03)."( Effect of itopride on gastric emptying in longstanding diabetes mellitus.
Giguère, M; Horowitz, M; Jones, KL; Maddox, AF; Phillips, L; Rayner, CK; Russo, A; Stevens, JE; Talley, NJ, 2008
)
1.2

Toxicity

ExcerptReferenceRelevance
" None of the patients reported any adverse events with itopride treatment."( Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia.
Amarapurkar, DN; Rane, P, 2004
)
0.79
"01), respectively and there were no differences in any secondary outcomes or adverse events between the two groups."( The efficacy and safety of itopride in feeding intolerance of critically ill patients receiving enteral nutrition: a randomized, double-blind study.
Bassiouny, AM; Darweesh, EAG; El Borolossy, RM; Elmokadem, EM; Hanna, MG; Sabri, NA, 2021
)
0.92

Pharmacokinetics

The pharmacokinetic parameters of itopride, including peak plasma concentration (Cmax) and area under the plasma concentration versus time curve over 24 hours after dosing (AUC(0-24h), were determined by noncompartmental analysis.

ExcerptReferenceRelevance
" The formulations were compared using the pharmacokinetic parameters area under the plasma concentration-time curve (AUC(0-t)), area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) and peak plasma concentration (Cmax)."( Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers.
Agarwal, S; Bhaumik, U; Bose, A; Das, A; Ghosh, D; Pal, TK; Roy, B; Sahoo, BK, 2009
)
0.57
" Steady-state pharmacokinetic parameters of itopride, including peak plasma concentration (Cmax) and area under the plasma concentration versus time curve over 24 hours after dosing (AUC(0-24h)), were determined by noncompartmental analysis."( Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers.
Chee, DH; Cho, JY; Jang, IJ; Kim, TE; Lee, H; Lee, S; Yoon, S; Yu, KS, 2014
)
0.89
"01]), although Cmax was reached more slowly and was lower for itopride ER than for the IR formulation."( Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers.
Chee, DH; Cho, JY; Jang, IJ; Kim, TE; Lee, H; Lee, S; Yoon, S; Yu, KS, 2014
)
0.87
"The test and reference formulations had similar pharmacokinetic parameters in each condition studied."( Comparative pharmacokinetic evaluation of extended release itopride HCl pellets with once daily tablet formulation in healthy human subjects: a two treatment, four period crossover study in fasted and fed condition.
Ahmed, K; Anwer, S; Nasiri, MI; Qazi, F; Shoaib, MH; Siddiqui, F; Yousuf, RI; Zaheer, K, 2019
)
0.76

Bioavailability

At steady state, once-daily itopride ER at 150 mg has a bioavailability comparable with that of itop Ride IR at 50 mg given three times a day under fasting conditions. The objective of this study was to compare the bioavailability and tolerability of revaprazan and itopide combination therapy to those of equally dosed monotherapies.

ExcerptReferenceRelevance
"25 and the relative bioavailability of rabeprazole and itopride test and reference formulations was 98."( Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers.
Agarwal, S; Bhaumik, U; Bose, A; Das, A; Ghosh, D; Pal, TK; Roy, B; Sahoo, BK, 2009
)
0.82
"In the present study two different formulations containing 50 mg itopride HCl (N-[4-12-(dimethylamino)ethoxylbenzyl]-3,4-dimethoxybenzamide HCl, CAS 122898-67-3) were compared in 28 healthy male volunteers in order to compare the bioavailability and prove the bioequivalence."( Pharmacokinetic and bioequivalence study of itopride HCl in healthy volunteers.
Cha, KH; Cho, KJ; Cho, W; Hwang, SJ; Kim, JS; Kim, MS; Park, J, 2010
)
0.86
"The objective of this study was to compare the bioavailability and tolerability of revaprazan and itopride combination therapy to those of equally dosed monotherapies to acquire basic drug-drug interaction information about revaprazan."( Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers.
Bae, KS; Choi, HY; Jang, SB; Jin, SJ; Kim, MJ; Kim, YH; Lee, SJ; Lim, HS; Noh, YH; Sung, H, 2012
)
0.82
"This study was conducted to compare the oral bioavailability of an itopride extended-release (ER) formulation with that of the reference immediate-release (IR) formulation in the fasting state."( Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers.
Chee, DH; Cho, JY; Jang, IJ; Kim, TE; Lee, H; Lee, S; Yoon, S; Yu, KS, 2014
)
0.86
"At steady state, once-daily itopride ER at 150 mg has a bioavailability comparable with that of itopride IR at 50 mg given three times a day under fasting conditions."( Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers.
Chee, DH; Cho, JY; Jang, IJ; Kim, TE; Lee, H; Lee, S; Yoon, S; Yu, KS, 2014
)
0.92
"In this study, pharmacokinetics (PKs) and bioavailability of newly developed extended release (ER) Itopride HCl 150 mg encapsulated ER pellets (test) and 150 mg Ganaton ER once-daily (OD) tablets (reference) were compared and evaluated under fasted and fed conditions."( Comparative pharmacokinetic evaluation of extended release itopride HCl pellets with once daily tablet formulation in healthy human subjects: a two treatment, four period crossover study in fasted and fed condition.
Ahmed, K; Anwer, S; Nasiri, MI; Qazi, F; Shoaib, MH; Siddiqui, F; Yousuf, RI; Zaheer, K, 2019
)
0.97

Dosage Studied

The objective of this study was to compare the bioavailability and tolerability of revaprazan and itopride combination therapy to those of equally dosed monotherapies. Steady-state pharmacokinetic parameters, including peak plasma concentration (Cmax) and area under the plasma concentration versus time curve over 24 hours after dosing (AUC(0-24h), were determined by noncompartmental analysis.

ExcerptRelevanceReference
" The analysis of variance (ANOVA) and Student's t-test were applied to correlate the results of IH determination in dosage form by means of HPLC and HPTLC methods."( Chromatographic determination of itopride hydrochloride in the presence of its degradation products.
Agrawal, H; Kadam, SS; Kaul, N; Mahadik, KR; Maske, P; Rao, JR, 2005
)
0.61
"A new simple, economical, rapid, precise and accurate method for simultaneous determination of rabeprazole sodium and itopride hydrochloride in capsule dosage form has been developed."( Spectrophotometric simultaneous determination of rabeprazole sodium and itopride hydrochloride in capsule dosage form.
Dhavale, ND; Gandhi, SV; Jadhav, VY; Sabnis, SS, 2008
)
0.79
"In the ileum, itopride accelerated peristaltic velocity at higher dosage (10(-10)-10(-6) M) whereas neostigmine accelerated it only with a lower dosage (10(-10)-10(-9) M)."( Effect of itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro.
Kim, HS; Kim, YG; Lim, HC; Lim, JH; Park, H, 2008
)
1.11
" The gastro retentive dosage form of itiopride demonstrated significant antacid, anti-ulcer, and anti-GERD activity after 12 hours in comparison with the conventional dosage form."( Evaluation of anti-GERD activity of gastro retentive drug delivery system of itopride hydrochloride.
Goyal, AK; Panda, PK; Rath, G; Satapathy, T, 2010
)
0.59
"The objective of this study was to compare the bioavailability and tolerability of revaprazan and itopride combination therapy to those of equally dosed monotherapies to acquire basic drug-drug interaction information about revaprazan."( Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers.
Bae, KS; Choi, HY; Jang, SB; Jin, SJ; Kim, MJ; Kim, YH; Lee, SJ; Lim, HS; Noh, YH; Sung, H, 2012
)
0.82
" Steady-state pharmacokinetic parameters of itopride, including peak plasma concentration (Cmax) and area under the plasma concentration versus time curve over 24 hours after dosing (AUC(0-24h)), were determined by noncompartmental analysis."( Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers.
Chee, DH; Cho, JY; Jang, IJ; Kim, TE; Lee, H; Lee, S; Yoon, S; Yu, KS, 2014
)
0.89
" The proposed sensors displayed useful analytical characteristics for the determination of PAN and ITH in bulk powder, in laboratory prepared mixtures and in combined dosage forms with clear discrimination from several ions, sugars and some common drug excipients."( Novel potentiometric application for the determination of pantoprazole sodium and itopride hydrochloride in their pure and combined dosage form.
Abd El-Rahman, MK; El-Ragehy, NA; El-Zeany, BA; Ragab, MT; Ramadan, NK, 2015
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (84)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (2.38)18.2507
2000's35 (41.67)29.6817
2010's40 (47.62)24.3611
2020's7 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 88.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index88.68 (24.57)
Research Supply Index4.82 (2.92)
Research Growth Index5.61 (4.65)
Search Engine Demand Index154.36 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (88.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials36 (41.38%)5.53%
Reviews7 (8.05%)6.00%
Case Studies1 (1.15%)4.05%
Observational0 (0.00%)0.25%
Other43 (49.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]